Skip to main content
Equibles
LEXX logo

LEXX · Lexaria Bioscience Corp.

Track LEXX — free

Use LEXX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.21 +0.73 (+5.85%)
Rebalance outlook locked
Going-concern doubt — flagged Jul 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements.”
View the 10-Q filed Jul 13, 2026
Customer concentration — top customer 100% of revenue

One customer — 100% of revenue (the nine months ended May 31, 2026)

“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”

2 customers — 100% of revenue (the nine months ended May 31, 2025)

“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
View the 10-Q filed Jul 13, 2026
Market Cap
$20.61M
Shares
1.65M

LEXX metrics

45 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.48
Market cap
$20.61M

Price action

19 metrics
Price change (1W)
+7.5%
Price change (30D)
+162.6%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Beta
—
RSI (14D)
75.9
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
76,397
Relative volume
0.9
Average dollar volume
$783,838

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.65M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
106.3×
reciprocal yield 0.9%
P / book
4.4
reciprocal yield 23.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-37.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-3,973.2%
Trailing 12 months
Net margin
-3,985.6%
Gross profit (TTM)
$194,000
Operating profit (TTM)
−$7.71M
Net income (TTM)
−$7.73M
Trailing 12 months
Diluted EPS (TTM)
$-5.25
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$30.04

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$194,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+35.6%
Year over year · more shares
Revenue CAGR (3Y)
+40.3%
Revenue CAGR (5Y)
+17.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-163.2%
Return on assets
-161.7%
Debt / equity
—
Current ratio
10.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.64M
Latest balance sheet
Cash & equivalents
$3.50M
Total assets
$4.78M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.43M
Capital expenditures (TTM)
—
R&D (TTM)
$4.00M
SG&A (TTM)
—
Stock compensation (TTM)
$365,458
R&D / revenue
2,061.7%
Stock compensation / revenue
188.4%

Ownership (13F)

3 metrics
13F filers
31
13F filer change QoQ
+3
Institutional ownership
6.6%

Short interest

3 metrics
Short interest
1.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1348362 CUSIP 52886N406 13F (30d) 27 filings 27 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)